| Mollie Mahanna Flahaven, NP, RN | |
|
46 Barra Rd, Biddeford, ME 04005-9459 | |
| (207) 282-3349 | |
| (207) 294-8898 |
| Full Name | Mollie Mahanna Flahaven |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 20 Years |
| Location | 46 Barra Rd, Biddeford, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922062025 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | RN48244 (Maine) | Secondary |
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | CNP81173 (Maine) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
News Archive
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Henry Ford Hospital researchers have brought the use of electronic medical records out of the hospital setting and into the streets by using the technology for a marathon.
Biovica has acquired cSens AB, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness.
The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead's Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment - $1000 per pill.
› Verified 1 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Henry Ford Hospital researchers have brought the use of electronic medical records out of the hospital setting and into the streets by using the technology for a marathon.
Biovica has acquired cSens AB, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness.
The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead's Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment - $1000 per pill.
› Verified 1 days ago
| Entity Name | Southern Maine Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659392819 PECOS PAC ID: 0143208348 Enrollment ID: O20040713001060 |
News Archive
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Henry Ford Hospital researchers have brought the use of electronic medical records out of the hospital setting and into the streets by using the technology for a marathon.
Biovica has acquired cSens AB, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness.
The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead's Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment - $1000 per pill.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mollie Mahanna Flahaven, NP, RN 78 Atlantic Pl, South Portland, ME 04106-2316 Ph: (207) 661-6654 | Mollie Mahanna Flahaven, NP, RN 46 Barra Rd, Biddeford, ME 04005-9459 Ph: (207) 282-3349 |
News Archive
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Henry Ford Hospital researchers have brought the use of electronic medical records out of the hospital setting and into the streets by using the technology for a marathon.
Biovica has acquired cSens AB, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness.
The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead's Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment - $1000 per pill.
› Verified 1 days ago
Halee Storey, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 22 W Cole Rd Ste 101, Biddeford, ME 04005 Phone: 207-780-6565 | |
Ms. Jamie Osgood Wendt, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 9 Healthcare Dr, Biddeford, ME 04005 Phone: 207-282-4270 | |
Kali Ann Waters, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 9 Healthcare Dr, Biddeford, ME 04005 Phone: 207-283-1427 | |
Heather J Lemire, WHNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 9 Healthcare Drive, Suite 101, Biddeford, ME 04005 Phone: 207-282-4270 Fax: 207-272-7350 | |
Lindsey Lucas, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 46 Barra Rd, Biddeford, ME 04005 Phone: 207-282-3349 | |
Lorraine Ware Rioux, ANP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Biddeford, ME 04005 Phone: 207-283-7454 Fax: 207-283-7476 | |
Christopher John Krupa-schayer, APRN, AGACNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 9 Healthcare Dr Ste 105, Biddeford, ME 04005 Phone: 207-282-3666 |